Phase III study evaluating prophylactic concizumab for haemophilia A and B terminated early
The trial was terminated due to reports of increased non-fatal thrombotic events.
Source:
PharmaTimes
The trial was terminated due to reports of increased non-fatal thrombotic events.
PharmaTimes